CA2267162A1 - System to reduce defibrillation requirements - Google Patents
System to reduce defibrillation requirements Download PDFInfo
- Publication number
- CA2267162A1 CA2267162A1 CA002267162A CA2267162A CA2267162A1 CA 2267162 A1 CA2267162 A1 CA 2267162A1 CA 002267162 A CA002267162 A CA 002267162A CA 2267162 A CA2267162 A CA 2267162A CA 2267162 A1 CA2267162 A1 CA 2267162A1
- Authority
- CA
- Canada
- Prior art keywords
- pacing
- defibrillation
- shock
- electrode
- level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/38—Applying electric currents by contact electrodes alternating or intermittent currents for producing shock effects
- A61N1/39—Heart defibrillators
- A61N1/3956—Implantable devices for applying electric shocks to the heart, e.g. for cardioversion
- A61N1/3962—Implantable devices for applying electric shocks to the heart, e.g. for cardioversion in combination with another heart therapy
- A61N1/39622—Pacing therapy
Abstract
A hybrid tachyarrhythmia therapy utilizes a combination of two therapies:
pacing therapy (optionally followed by therapy employing waveforms having morphologies congruent to defibrillation waveforms but at reduced strength);
and defibrillation (including cardioversion) therapy. The two therapies are applied in either a temporally concident, or an immediately sequential, fashion. At least one pacing pulse that influences only a localized portion of selected cardiac tissue is applied, prior to or coincident with at least one defibrillation-level shock. The defibrillation shock strength (voltage and/or energy) required to terminate the tachyarrhythmia is less than would be required in the absence of the critically coupled pacing pulses. The therapy may be applied to atrial or ventricular tachyarrhythmias. A variety of electrode configurations and defibrillation pulse schemes may be employed.
pacing therapy (optionally followed by therapy employing waveforms having morphologies congruent to defibrillation waveforms but at reduced strength);
and defibrillation (including cardioversion) therapy. The two therapies are applied in either a temporally concident, or an immediately sequential, fashion. At least one pacing pulse that influences only a localized portion of selected cardiac tissue is applied, prior to or coincident with at least one defibrillation-level shock. The defibrillation shock strength (voltage and/or energy) required to terminate the tachyarrhythmia is less than would be required in the absence of the critically coupled pacing pulses. The therapy may be applied to atrial or ventricular tachyarrhythmias. A variety of electrode configurations and defibrillation pulse schemes may be employed.
Description
SYSTEM TO REDUCE DEFIBRILLATION REQUIREMENTS
The classic definition of defibrillation is simply the termination of fibrillation. Fibrillation is a condition in which rapidly changing wavefronts of myocardial activation circulate within heart tissue and prevent coordinated mechanical contractions of cardiac muscle as a whole, thus reducing or eliminating the hemodynamic benefit produced by the contractions. Normally, defibrillation is accomplished with transthoracic electrical shocks in the range of approximately 100-400 Joules; or shocks in the range of approximately 2-30 Joules applied internally to the chest, either between a plurality of areal ("patch") electrodes, or between a plurality of endocardial catheter electrodes, the plurality of electrodes including at least one electrode located on or distant from the heart. The term "pulse" is sometimes used interchangeably with "shock." Both are used here to 1 S denote either voltage or current discharge from an energy storage device, such as a capacitor or capacitor bank, as indicated by a plot of either voltage or current as a fimction of time.
In contrast to defibrillation, cardioversion therapy is applied during situations when heart rhythms are comparatively organized, but occurring too rapidly to allow hemodynamic stability. In these cases, cardioversion shocks are delivered at or very near the peak of the sensed ventricular depolarization (i.e., the QRS complex). Typical cardioversion shocks are in the range of approximately 200 Joules if delivered transthoracically, or 0.05-2 Joules if delivered internally.
Pacing pulses of the type used for bradycardia therapy or antitachycardia pacing are those which have energies on the order of microjoules, and thus are well below the energy level of defibrillation or cardioversion shocks.
The low conversion energy benefits of internal defibrillation are the basis of the commercially available system commonly known as the automatic implantable defibrillator (A>D) and other similar names. Such systems are generally fully implantable and include a computer-controlled pulse generator to detect, diagnose, and treat hemodynamically unstable rhythms which spontaneously occur in patients.
Typically, these systems sense the presence of a potentially lethal arrhythmia by continually monitoring rate and morphology features from sensed cardiac electrograms; diagnose known clinically treatable arrhythmias by comparing the rate and morphology features to pre-programmed and/or adaptive criteria; and deliver a high (up to approximately 40 Joules, depending on the manufacturer and model) shock to terminate the unfavorable rhythm and restore coordinated mechanical pumping function. The most advanced of the currently commercialized devices use a tiered therapy approach, in which a pre-programmed therapy is automatically selected, based on certain rhythm classification criteria. For example, slow, monomorphic, hemodynamically stable ventricular tachyarrhythmia (VT) may be treated with pacing (~ 40 microjoule) therapies, e.g., antitachyarrhythmia pacing (ATP), while fast, polymorphic, hemodynamically unstable rhythms may be treated with low strength (0.05-2 Joules) shocks followed by higher strength (2-4.0 Joules) shocks if earlier interventions fail. For primary ventricular fibrillation (VF), only high strength (typically at least 10 Joules) def brillation shocks are prescribed. In general, the morphology of the defibrillation waveform affects the amount of energy needed for successful therapy. Biphasic shocks usually require less energy than monophasic shocks, although exceptions have been observed.
Experimental variations on these commercially available designs attempt to "pretreat" the arrhythmia, especially fibrillation, with electrical stimulation to metamorphose the arrhythmia into a more easily treated arrhythmia; or, at least into an arrhythmia which does not require as much of the limited energy available for clinically desirable attempts. For example, a successful pretreatment scheme would lower the energy subsequently used in a defibrillation attempt from approximately 20-40 Joules to approximately 10 Joules. If the attempt is successful at the lower energy level, side effects (i.e., pain, long-term damage to the myocardium, etc.) are minimized. Even if the defibrillation attempt is not successful, the reduction in energy helps ensure that adequate energy from the limited battery supply is available for a subsequent, higher energy attempt.
The first comprehensive scheme of this type may be that of US Patent 4,559,946 (Mower). In this approach, a series of relatively low-energy (0.1-Joules) pulses is used to successively "capture" increasing amounts of myocardium and subsequently achieve defibrillation by the succession of shocks, even through each low-energy shock might be ineffective by itself for this purpose.
Specifically, the configuration of the arrhythmia is "coarsened," i.e., the 10 configuration of the arrhythmia is altered primarily by reduction of frequency or increase of amplitude. Thus, for example, ventricular fibrillation is coarsened into ventricular tachycardia or ventricular flutter, or a low amplitude ventricular tachycardia pattern is changed to a high amplitude pattern which is easier to treat.
The time between pulses varies firom about ten milliseconds to about five seconds, 1 S preferably 80 milliseconds to 1.5 seconds. For safety, fizll "backup"
defibrillation capabilities (i.e., energies on the order of 30-35 Joules) are available.
US Patent 4,693,253 (Adams) discloses a circuit suitable for using residual energy available from the defibrillation capacitors for stimulation of the cardiac tissue if normal sinus rhythm is not promptly reestablished. The stimulation occurs after the defibrillation shock, rather than before the shock as disclosed by Mower.
No specific energy levels, timing parameters, or therapeutic objectives are discussed; however, the residual energy can be used at the voltage at which it appears on the defibrillation capacitors after a shock has been delivered, or it can be reduced to unspecified lower levels. Electrode configurations are shown only schematically, but it appears that the same electrodes are used for defibrillation as for delivery of the post-defibrillation stimulation even though the latter is called "pacing."
A more comprehensive scheme is that of US Patents 5,366,485 (Knoll et al.) and 5,522,853 (Knoll). The first of these two patents discloses application of either a single low-energy, long-duration pretreatment pulse or a plurality of low-energy pretreatment pulses, specifically a train of low-energy pulses, spaced away from the def brillation pulse by a time interval. The same electrodes are used for pretreatment and defibrillation, but it is not necessarily true that the pretreatment energy arises from the capacitors used to generate the defibrillation pulse.
The goal of this particular pretreatment scheme is temporal and spatial organization of significant portions of the heart, so that the subsequent defibrillation pulse can succeed with lower energy required than would otherwise be required.
Similarly, the second patent discloses matching a series of "recruitment"
pulses on the order of approximately 1 Joule per pulse to the inherent frequency of the fibrillation wavefonn, typically four to ten Hertz, thus successively capturing regions of fibrillating tissue and thus coordinating activation wavefronts such that a defibrillation pulse can be timed to successfully convert the fibrillation at a lower energy level. In one disclosed example, the recruitment pulses are biphasic with each phase duration less than 500 milliseconds; a preferred configuration uses a first phase duration of approximately 300 ms and a second phase duration of approximately 200 ms. The timing of the recruitment pulses is somewhat flexible;
disclosed examples include a fixed percentage (e.g., 85%) of the intrinsic fibrillation rate as determined in a variety of manners, as well as a value which dynamically varies in response to instantaneous sensing and analysis of the intrinsic fibrillation rate (as from a separate bipolar electrode). The polarity of the pulses can reverse within a train of pulses. Also, the discharge pathway of successive recruitment pulses can selectively vary within the train of pulses, and thus presumably the recruitment pulses could be delivered from electrodes not used for the subsequent defibrillation pulse.
Other schemes are those of US Patents 5,431,682 (Hedberg) and 5,464,429 (Hedberg et al.). The first of these two patents discloses application of relatively lower energy (0.4 millijoule to 20 Joules) stimulation pulses after the defibrillation pulse to enable effective pacing of the heart in the vicinity of the defibrillation electrode. The delay between the defibrillation pulse and the first post-defibrillation pulse is variable, as is the rate of the post-defibrillation pulses, which can be monophasic or biphasic.
The second patent discloses application of a series of relatively low energy 5 (1 millijoule) pulses across the range of relative timing choices, i.e., either prior to a defibrillation shock, or between multiple defibrillation shocks, or after a defibrillation shock. The pulses are typically 20-200 ms apart. The pulses are delivered through intracardiac or epicardiac electrodes normally used for pacing.
The stimulation pulses produce a refractory area around the stimulation electrode for stopping fibrillation activity.
disclosure of Invention The invention provides a system for supplying therapeutic electrical energy, and comprises a first generator of at least one pacing level shock, a second generator of at least one defibrillation-level shock, where this system is characterized by a first electrode system coupled to the first generator for delivering the at least one pacing level shock to a first location including at least a region of selected cardiac tissue having a relatively low susceptibility to defibrillation-level shock field strength, and a second electrode system coupled to the second generator for delivering the defibrillation-Level shock to the heart from a second location, in which the system fiuther comprises timers which coordinate delivery of a first defibrillation-level shock with the delivery of the at least one pacing level shock.
The invention further provides a system for supplying a single electrical therapy to a selected region of selected cardiac tissue, comprising the combination of two discrete system functions: providing pacing level therapy applied to a localized portion of a region of the selected cardiac tissue having relatively low susceptibility to defibrillation-level shock field strengths; followed by (or occurring simultaneously or concurrently with) defibrillation therapy applied to portions of the tissue having regions of fibrillating myocardium over which the sub-defibrillation-WO 98/13102 . PCT/US97/17233 level shocks exert control; such regions of fibrillating myocardium are those characterized by approximately a 1:1 phase lock of a local electrogram of any region to a stimulus artifact of that region.
Thus, in another sense, the invention provides a system for the application of at least one exogenous pacing level shock to regions of fibrillating myocardium within selected cardiac tissue, any such region being characterized by approximately a 1:1 phase lock of a local electrogram of that region to a stimulus artifact in that region, such that invasion of intrinsic fibrillation wavefronts into at least one region of fibrillating myocardium is prevented.
Regardless of how the invention is described, the advantage of the invention is that the strength (voltage and/or energy) required for successful defibrillation by the first defibrillation-level shock delivered by the system is reduced. This is because, while the region controlled by the pacing level shocks may be only the same size as the localized region, the goal of the is for the successive regions of fibrillating myocardium to be successively larger in terms of the amount of tissue controlled. A successively larger amount of controlled tissue increases the probability that the entire heart may be successfully treated by a single defibrillation shock, and especially so by a single defibrillation shock of reduced strength than would be possible otherwise.
In any embodiment of the invention, the selected cardiac tissue may be ventricular tissue, or it may be atrial tissue; in the latter case, the first defibrillation shock which would otherwise occur within the vulnerable period (T-wave) of the ventricular activation cycle, should not occur until after ventricular depolarization.
The first defibrillation-level shock occurs at least as soon as (i.e., coincident with or after) the last pacing level shock; preferably, the last pacing level shock occurs not sooner than the beginning of an optimum period beginning before the first defibrillation-level shock. This period can be determined by extracting a feature from sensed cardiac signals, such as morphology of the ECG or some component of the ECG; some fraction (e.g., 80-I00%) of the cardiac cycle length, etc. The exact condition used to determine the optimum period is determined empirically by the particular clinical and therapeutic context; however, typical practical limits on the optimum period would be from 250 milliseconds prior to the first defibrillation shock, to coincident (or simultaneously), i.e., within less than one S millisecond, with the first defibrillation shock.
By appropriate designation of the region of selected cardiac tissue, it is possible to supply the system of the invention to the treatment of characteristically different arrhythmias, provided that the arrhythmias are convertible to other states "closer" to (if not actually the state of) normal sinus rhythm. That is, if an arrhythmia is known to be convertible to a condition of increased periodicity, then a more predictable conversion of the arrhythmia is possible. Typical conversions are to normal sinus rhythm, or to near-normal sinus rhythm, in a single defibrillation shock, but in mufti-shock situations it is possible that the conversion will simply be to an intermediate state, i.e., one which may in turn be converted to normal sinus rhythm by application of at least one additional shock. In a "near-normal"
sinus rhythm, the heart rate is greater than normal sinus rhythm, but the heart is hemodynamically stable. (Near-normal sinus rhythm is itself an example of such an intermediate state.) Thus, the invention may be practiced in situations in which a plurality of different shock strength profiles is applied to a plurality of regions of the selected cardiac tissue, the regions having characteristically different arrhythmias convertible to other states by mechanisms which differ from each other. Each of the plurality of shock strength profiles is selected to correspond to each of the plurality of regions according to the ability of the profile to provide increased periodicity in each region. Use of the invention is successful if predictable activation is created in at least one particular region.
The preferred embodiment is a series of pacing level shocks, which is readily provided by known pacing techniques.
Specific physical embodiments of the invention treat cardiac arrhythmia by according to the steps of: (a) determining a region of selected cardiac tissue having WO 98/13102 - PCT/US97f17233 relatively low susceptibility to defibrillation-level shock field strength;
(b) applying at least one pacing level shock to a localized portion of the region of selected cardiac tissue; and (c) applying at least one defibrillation-level shock to the heart, but not before step (b) has occurred. Thus, the defibrillation-level shock is applied prior to or simultaneously with the last pacing level shock; but the last {i.e., the only, if a single pacing pulse is used) pacing level shock should occur within one mean activation interval prior to the first.
The system of the present invention comprises a pulse generator subsystem capable of providing pacing level and defibrillation-level shocks, and an electrode system positioned with respect to the selected cardiac tissue such that the pacing level shocks may be applied to regions of the tissue where the defibrillation-level shock-included field intensity is weak. An electrode system is a single, composite, or multiple member device providing the common fiulctions of electrodes -sensing, pacing, and shocking - at the subcutaneous, epicardial, myocardial, or endocardial locations, and introduced to the cardiac tissue directly or transvenously.
Electrodes can be either anodic or cathodic, as required by the application. The housing containing the pulse generator subsystem, if implantable, may itself be an electrode (anode or cathode), either as a supplemental electrode to an endocardial, myocardial, or epicardial electrode, or as a free-standing electrode.
The pulse generator subsystem may comprise separate pacing level and defibrillation-level units, but devices combining these two functions into a single implantable pulse generator are preferred.
While any portion of the system other than the shocking and sensing portions of the electrodes may be external to the patient, a fully implantable system is preferred.
Descn_ption of the Drawing Figures 1-4 are schematic cross-sectional view of a heart and electrodes positioned according to respective embodiments of the invention.
The classic definition of defibrillation is simply the termination of fibrillation. Fibrillation is a condition in which rapidly changing wavefronts of myocardial activation circulate within heart tissue and prevent coordinated mechanical contractions of cardiac muscle as a whole, thus reducing or eliminating the hemodynamic benefit produced by the contractions. Normally, defibrillation is accomplished with transthoracic electrical shocks in the range of approximately 100-400 Joules; or shocks in the range of approximately 2-30 Joules applied internally to the chest, either between a plurality of areal ("patch") electrodes, or between a plurality of endocardial catheter electrodes, the plurality of electrodes including at least one electrode located on or distant from the heart. The term "pulse" is sometimes used interchangeably with "shock." Both are used here to 1 S denote either voltage or current discharge from an energy storage device, such as a capacitor or capacitor bank, as indicated by a plot of either voltage or current as a fimction of time.
In contrast to defibrillation, cardioversion therapy is applied during situations when heart rhythms are comparatively organized, but occurring too rapidly to allow hemodynamic stability. In these cases, cardioversion shocks are delivered at or very near the peak of the sensed ventricular depolarization (i.e., the QRS complex). Typical cardioversion shocks are in the range of approximately 200 Joules if delivered transthoracically, or 0.05-2 Joules if delivered internally.
Pacing pulses of the type used for bradycardia therapy or antitachycardia pacing are those which have energies on the order of microjoules, and thus are well below the energy level of defibrillation or cardioversion shocks.
The low conversion energy benefits of internal defibrillation are the basis of the commercially available system commonly known as the automatic implantable defibrillator (A>D) and other similar names. Such systems are generally fully implantable and include a computer-controlled pulse generator to detect, diagnose, and treat hemodynamically unstable rhythms which spontaneously occur in patients.
Typically, these systems sense the presence of a potentially lethal arrhythmia by continually monitoring rate and morphology features from sensed cardiac electrograms; diagnose known clinically treatable arrhythmias by comparing the rate and morphology features to pre-programmed and/or adaptive criteria; and deliver a high (up to approximately 40 Joules, depending on the manufacturer and model) shock to terminate the unfavorable rhythm and restore coordinated mechanical pumping function. The most advanced of the currently commercialized devices use a tiered therapy approach, in which a pre-programmed therapy is automatically selected, based on certain rhythm classification criteria. For example, slow, monomorphic, hemodynamically stable ventricular tachyarrhythmia (VT) may be treated with pacing (~ 40 microjoule) therapies, e.g., antitachyarrhythmia pacing (ATP), while fast, polymorphic, hemodynamically unstable rhythms may be treated with low strength (0.05-2 Joules) shocks followed by higher strength (2-4.0 Joules) shocks if earlier interventions fail. For primary ventricular fibrillation (VF), only high strength (typically at least 10 Joules) def brillation shocks are prescribed. In general, the morphology of the defibrillation waveform affects the amount of energy needed for successful therapy. Biphasic shocks usually require less energy than monophasic shocks, although exceptions have been observed.
Experimental variations on these commercially available designs attempt to "pretreat" the arrhythmia, especially fibrillation, with electrical stimulation to metamorphose the arrhythmia into a more easily treated arrhythmia; or, at least into an arrhythmia which does not require as much of the limited energy available for clinically desirable attempts. For example, a successful pretreatment scheme would lower the energy subsequently used in a defibrillation attempt from approximately 20-40 Joules to approximately 10 Joules. If the attempt is successful at the lower energy level, side effects (i.e., pain, long-term damage to the myocardium, etc.) are minimized. Even if the defibrillation attempt is not successful, the reduction in energy helps ensure that adequate energy from the limited battery supply is available for a subsequent, higher energy attempt.
The first comprehensive scheme of this type may be that of US Patent 4,559,946 (Mower). In this approach, a series of relatively low-energy (0.1-Joules) pulses is used to successively "capture" increasing amounts of myocardium and subsequently achieve defibrillation by the succession of shocks, even through each low-energy shock might be ineffective by itself for this purpose.
Specifically, the configuration of the arrhythmia is "coarsened," i.e., the 10 configuration of the arrhythmia is altered primarily by reduction of frequency or increase of amplitude. Thus, for example, ventricular fibrillation is coarsened into ventricular tachycardia or ventricular flutter, or a low amplitude ventricular tachycardia pattern is changed to a high amplitude pattern which is easier to treat.
The time between pulses varies firom about ten milliseconds to about five seconds, 1 S preferably 80 milliseconds to 1.5 seconds. For safety, fizll "backup"
defibrillation capabilities (i.e., energies on the order of 30-35 Joules) are available.
US Patent 4,693,253 (Adams) discloses a circuit suitable for using residual energy available from the defibrillation capacitors for stimulation of the cardiac tissue if normal sinus rhythm is not promptly reestablished. The stimulation occurs after the defibrillation shock, rather than before the shock as disclosed by Mower.
No specific energy levels, timing parameters, or therapeutic objectives are discussed; however, the residual energy can be used at the voltage at which it appears on the defibrillation capacitors after a shock has been delivered, or it can be reduced to unspecified lower levels. Electrode configurations are shown only schematically, but it appears that the same electrodes are used for defibrillation as for delivery of the post-defibrillation stimulation even though the latter is called "pacing."
A more comprehensive scheme is that of US Patents 5,366,485 (Knoll et al.) and 5,522,853 (Knoll). The first of these two patents discloses application of either a single low-energy, long-duration pretreatment pulse or a plurality of low-energy pretreatment pulses, specifically a train of low-energy pulses, spaced away from the def brillation pulse by a time interval. The same electrodes are used for pretreatment and defibrillation, but it is not necessarily true that the pretreatment energy arises from the capacitors used to generate the defibrillation pulse.
The goal of this particular pretreatment scheme is temporal and spatial organization of significant portions of the heart, so that the subsequent defibrillation pulse can succeed with lower energy required than would otherwise be required.
Similarly, the second patent discloses matching a series of "recruitment"
pulses on the order of approximately 1 Joule per pulse to the inherent frequency of the fibrillation wavefonn, typically four to ten Hertz, thus successively capturing regions of fibrillating tissue and thus coordinating activation wavefronts such that a defibrillation pulse can be timed to successfully convert the fibrillation at a lower energy level. In one disclosed example, the recruitment pulses are biphasic with each phase duration less than 500 milliseconds; a preferred configuration uses a first phase duration of approximately 300 ms and a second phase duration of approximately 200 ms. The timing of the recruitment pulses is somewhat flexible;
disclosed examples include a fixed percentage (e.g., 85%) of the intrinsic fibrillation rate as determined in a variety of manners, as well as a value which dynamically varies in response to instantaneous sensing and analysis of the intrinsic fibrillation rate (as from a separate bipolar electrode). The polarity of the pulses can reverse within a train of pulses. Also, the discharge pathway of successive recruitment pulses can selectively vary within the train of pulses, and thus presumably the recruitment pulses could be delivered from electrodes not used for the subsequent defibrillation pulse.
Other schemes are those of US Patents 5,431,682 (Hedberg) and 5,464,429 (Hedberg et al.). The first of these two patents discloses application of relatively lower energy (0.4 millijoule to 20 Joules) stimulation pulses after the defibrillation pulse to enable effective pacing of the heart in the vicinity of the defibrillation electrode. The delay between the defibrillation pulse and the first post-defibrillation pulse is variable, as is the rate of the post-defibrillation pulses, which can be monophasic or biphasic.
The second patent discloses application of a series of relatively low energy 5 (1 millijoule) pulses across the range of relative timing choices, i.e., either prior to a defibrillation shock, or between multiple defibrillation shocks, or after a defibrillation shock. The pulses are typically 20-200 ms apart. The pulses are delivered through intracardiac or epicardiac electrodes normally used for pacing.
The stimulation pulses produce a refractory area around the stimulation electrode for stopping fibrillation activity.
disclosure of Invention The invention provides a system for supplying therapeutic electrical energy, and comprises a first generator of at least one pacing level shock, a second generator of at least one defibrillation-level shock, where this system is characterized by a first electrode system coupled to the first generator for delivering the at least one pacing level shock to a first location including at least a region of selected cardiac tissue having a relatively low susceptibility to defibrillation-level shock field strength, and a second electrode system coupled to the second generator for delivering the defibrillation-Level shock to the heart from a second location, in which the system fiuther comprises timers which coordinate delivery of a first defibrillation-level shock with the delivery of the at least one pacing level shock.
The invention further provides a system for supplying a single electrical therapy to a selected region of selected cardiac tissue, comprising the combination of two discrete system functions: providing pacing level therapy applied to a localized portion of a region of the selected cardiac tissue having relatively low susceptibility to defibrillation-level shock field strengths; followed by (or occurring simultaneously or concurrently with) defibrillation therapy applied to portions of the tissue having regions of fibrillating myocardium over which the sub-defibrillation-WO 98/13102 . PCT/US97/17233 level shocks exert control; such regions of fibrillating myocardium are those characterized by approximately a 1:1 phase lock of a local electrogram of any region to a stimulus artifact of that region.
Thus, in another sense, the invention provides a system for the application of at least one exogenous pacing level shock to regions of fibrillating myocardium within selected cardiac tissue, any such region being characterized by approximately a 1:1 phase lock of a local electrogram of that region to a stimulus artifact in that region, such that invasion of intrinsic fibrillation wavefronts into at least one region of fibrillating myocardium is prevented.
Regardless of how the invention is described, the advantage of the invention is that the strength (voltage and/or energy) required for successful defibrillation by the first defibrillation-level shock delivered by the system is reduced. This is because, while the region controlled by the pacing level shocks may be only the same size as the localized region, the goal of the is for the successive regions of fibrillating myocardium to be successively larger in terms of the amount of tissue controlled. A successively larger amount of controlled tissue increases the probability that the entire heart may be successfully treated by a single defibrillation shock, and especially so by a single defibrillation shock of reduced strength than would be possible otherwise.
In any embodiment of the invention, the selected cardiac tissue may be ventricular tissue, or it may be atrial tissue; in the latter case, the first defibrillation shock which would otherwise occur within the vulnerable period (T-wave) of the ventricular activation cycle, should not occur until after ventricular depolarization.
The first defibrillation-level shock occurs at least as soon as (i.e., coincident with or after) the last pacing level shock; preferably, the last pacing level shock occurs not sooner than the beginning of an optimum period beginning before the first defibrillation-level shock. This period can be determined by extracting a feature from sensed cardiac signals, such as morphology of the ECG or some component of the ECG; some fraction (e.g., 80-I00%) of the cardiac cycle length, etc. The exact condition used to determine the optimum period is determined empirically by the particular clinical and therapeutic context; however, typical practical limits on the optimum period would be from 250 milliseconds prior to the first defibrillation shock, to coincident (or simultaneously), i.e., within less than one S millisecond, with the first defibrillation shock.
By appropriate designation of the region of selected cardiac tissue, it is possible to supply the system of the invention to the treatment of characteristically different arrhythmias, provided that the arrhythmias are convertible to other states "closer" to (if not actually the state of) normal sinus rhythm. That is, if an arrhythmia is known to be convertible to a condition of increased periodicity, then a more predictable conversion of the arrhythmia is possible. Typical conversions are to normal sinus rhythm, or to near-normal sinus rhythm, in a single defibrillation shock, but in mufti-shock situations it is possible that the conversion will simply be to an intermediate state, i.e., one which may in turn be converted to normal sinus rhythm by application of at least one additional shock. In a "near-normal"
sinus rhythm, the heart rate is greater than normal sinus rhythm, but the heart is hemodynamically stable. (Near-normal sinus rhythm is itself an example of such an intermediate state.) Thus, the invention may be practiced in situations in which a plurality of different shock strength profiles is applied to a plurality of regions of the selected cardiac tissue, the regions having characteristically different arrhythmias convertible to other states by mechanisms which differ from each other. Each of the plurality of shock strength profiles is selected to correspond to each of the plurality of regions according to the ability of the profile to provide increased periodicity in each region. Use of the invention is successful if predictable activation is created in at least one particular region.
The preferred embodiment is a series of pacing level shocks, which is readily provided by known pacing techniques.
Specific physical embodiments of the invention treat cardiac arrhythmia by according to the steps of: (a) determining a region of selected cardiac tissue having WO 98/13102 - PCT/US97f17233 relatively low susceptibility to defibrillation-level shock field strength;
(b) applying at least one pacing level shock to a localized portion of the region of selected cardiac tissue; and (c) applying at least one defibrillation-level shock to the heart, but not before step (b) has occurred. Thus, the defibrillation-level shock is applied prior to or simultaneously with the last pacing level shock; but the last {i.e., the only, if a single pacing pulse is used) pacing level shock should occur within one mean activation interval prior to the first.
The system of the present invention comprises a pulse generator subsystem capable of providing pacing level and defibrillation-level shocks, and an electrode system positioned with respect to the selected cardiac tissue such that the pacing level shocks may be applied to regions of the tissue where the defibrillation-level shock-included field intensity is weak. An electrode system is a single, composite, or multiple member device providing the common fiulctions of electrodes -sensing, pacing, and shocking - at the subcutaneous, epicardial, myocardial, or endocardial locations, and introduced to the cardiac tissue directly or transvenously.
Electrodes can be either anodic or cathodic, as required by the application. The housing containing the pulse generator subsystem, if implantable, may itself be an electrode (anode or cathode), either as a supplemental electrode to an endocardial, myocardial, or epicardial electrode, or as a free-standing electrode.
The pulse generator subsystem may comprise separate pacing level and defibrillation-level units, but devices combining these two functions into a single implantable pulse generator are preferred.
While any portion of the system other than the shocking and sensing portions of the electrodes may be external to the patient, a fully implantable system is preferred.
Descn_ption of the Drawing Figures 1-4 are schematic cross-sectional view of a heart and electrodes positioned according to respective embodiments of the invention.
Figure S is a schematic timing diagram of one embodiment of the invention.
Figure SA is a detail of the schematic timing diagram of Figure 5.
Figures 6, 7 and 8 are schematic cross-sectional views of a heart and electrodes positioned according to respective embodiments of the invention.
Figure 9 is a schematic timing diagram of an alternative embodiment of the invention.
Figure 10 is a schematic block diagram of a system embodiment of the invention.
Detailed Descn~~tion As in the known variations on the classic "single therapy" approach to defibrillation described above, the invention is based on simultaneous or near-simultaneous combination of two therapies, pacing level shocks (~ 1-10 V) and defibrillation (including cardioversion) shocks (~ 200-800 V level). This invention utilizes both pacing level shocks and defibrillation shocks in either a temporally coincident, or an immediately sequential, fashion. The inventive therapy constitutes a hybrid, combination tachyarrhythmia therapy referred to here as "defibroversion."
Defibroversion therapy is produced by applying a rapid series of pacing pulses that influence only a localized portion of selected cardiac tissue, in addition to at least one defibrillation-level shock.
Defibroversion may be implemented in any of several physical configurations. In general, defibroversion requires implantation of defibrillation electrodes in, on or riear the heart such that when defibrillation-level shocks are applied, the regions of weak field intensity are located in a region that is accessible by conventional techniques for introduction and fixation of pacing electrodes in or immediately adjacent to that region. Pacing level shocks are then applied to the heart tissue in the area of the heart where the defibrillation-level shock fields are known to be weak. In this way, tissue in the weak field area is actively stimulated and locally controlled by the pacing pulses. If a suitable column of tissue has been influenced, a defibrillation-level shock is applied at a time based on predetermined timing criteria. This provides an optimum coupling interval between the last controlled beat and the first higher level shock.
In practice, the preferred optimum coupling interval ranges from less than 5 one millisecond (i.e., "simultaneously") to about 200-250 ms. However, because the invention is applicable to a variety of different arrhythmias, the coupling interval is best determined by optimization based upon one or more features extracted from the morphology and/or cycle length (or other timing parameters) of the cardiac rhythm as sensed prior to the defibrillation-level shock.
Figure SA is a detail of the schematic timing diagram of Figure 5.
Figures 6, 7 and 8 are schematic cross-sectional views of a heart and electrodes positioned according to respective embodiments of the invention.
Figure 9 is a schematic timing diagram of an alternative embodiment of the invention.
Figure 10 is a schematic block diagram of a system embodiment of the invention.
Detailed Descn~~tion As in the known variations on the classic "single therapy" approach to defibrillation described above, the invention is based on simultaneous or near-simultaneous combination of two therapies, pacing level shocks (~ 1-10 V) and defibrillation (including cardioversion) shocks (~ 200-800 V level). This invention utilizes both pacing level shocks and defibrillation shocks in either a temporally coincident, or an immediately sequential, fashion. The inventive therapy constitutes a hybrid, combination tachyarrhythmia therapy referred to here as "defibroversion."
Defibroversion therapy is produced by applying a rapid series of pacing pulses that influence only a localized portion of selected cardiac tissue, in addition to at least one defibrillation-level shock.
Defibroversion may be implemented in any of several physical configurations. In general, defibroversion requires implantation of defibrillation electrodes in, on or riear the heart such that when defibrillation-level shocks are applied, the regions of weak field intensity are located in a region that is accessible by conventional techniques for introduction and fixation of pacing electrodes in or immediately adjacent to that region. Pacing level shocks are then applied to the heart tissue in the area of the heart where the defibrillation-level shock fields are known to be weak. In this way, tissue in the weak field area is actively stimulated and locally controlled by the pacing pulses. If a suitable column of tissue has been influenced, a defibrillation-level shock is applied at a time based on predetermined timing criteria. This provides an optimum coupling interval between the last controlled beat and the first higher level shock.
In practice, the preferred optimum coupling interval ranges from less than 5 one millisecond (i.e., "simultaneously") to about 200-250 ms. However, because the invention is applicable to a variety of different arrhythmias, the coupling interval is best determined by optimization based upon one or more features extracted from the morphology and/or cycle length (or other timing parameters) of the cardiac rhythm as sensed prior to the defibrillation-level shock.
10 In one embodiment, as shown in Figure I, pacing pulses are administered from a transvenous lead (10) residing in or near the coronary sinus along the postern-basal region of the left ventricle (LV) or in the right ventricle (RV) outflow tract, while the defibrillation-level pulse is applied between endocardial electrodes (11 a,11 b) residing in the RV apex (electrode 1 I a) and in the superior vena cava (SVC) (electrode 11b) just proximal to or partially in the right atrium.
A second embodiment, as shown in Figure 2, is identical to the first with the exception that the defibrillation-level pulse is applied along a bi-directional pathway from the (now cathodic) RV electrode (11 a) to a common anode formed by two electrodes: one (11b) residing in the SVC (as before), the other (12) residing in the left lateral subcutis centered approximately on the mid-axillary Line. (In this, as in other embodiments, the roles of one electrode, or set of electrodes, as the anode and the other as the cathode can be interchanged without loss of generality to the invention.) Without loss of generality, the electrode (12) located in the left lateral subcutis can be an electrically active housing of the pulse generator, as discussed in more detail below.
In a third embodiment, as shown in Figure 3, the pacing-level pulses are delivered from a sutureless myocardial ("screw-in") lead (13) positioned in an apical region of the heart. Defibrillation-level pulses are applied between epicardial electrodes (14a,14b) positioned substantially opposite each other on the free walls of the ventricles.
Figure 4 shows a preferred location for a transvenous pacing electrode (15) which has been introduced into the coronary sinus, then into the great cardiac vein, and then into the ascending limb of either the anterior cardiac vein or the posterior cardiac vein, into the vasculature of the left ventricle. Because the courses of these veins are near the surface of the heart, this location gives performance very similar to that of the epicardial electrode discussed below, even though the location is within the cardiac vasculature. This embodiment places the pacing electrode (15) as close as possible to the apex of the left ventricle via a transvenous procedure, which is desirable to avoid a thoracotomy, median sternotomy, or other extensive surgical procedure.
In any of the embodiments above, an electrically active housing of the pulse generator can also serve as a defibrillation electrode, either in addition to the RV and SVC electrodes, or as a replacement to either (but typically not as a replacement for the RV electrode to ensure that sufficient ventricular mass is affected by the defibrillation shock).
The details of a scheme employing pacing-level pulses, applicable to any of the embodiments of Figures 1-4, are shown schematically in Figures 5 and SA.
The series of pacing-level pulses, denoted SP, is delivered during a period of hemodynamically unstable tachyarrhythmia, denoted schematically as VF (the tachyarrhythmia need not be only ventricular fibrillation, though that is a common condition). For this illustration, the pacing pulses have a cycle length (CL) of approximately 40 to 95 percent of the sensed cycle length of the local activations in the area of the heart in the region where the defibrillation-level shock field intensity is weak. The defibrillation shock is denoted SD.
(The defibrillation shock normally, but not necessarily, arises from a capacitor discharge and displays a biphasic truncated exponential pulse shape.
Such shocks are preferably produced by terminating the discharge waveform of a capacitor network (a single capacitor, or multiple capacitors, as dictated by morphology, available pulse generator volume, and other considerations) having capacitance in the range of 20-400 ~F; but any otherwise suitable device for producing the shocks may be employed. For example, the system of the present invention is applicable to defibrillation shocks arising from multiple-capacitor networks andlor monophasic or multiphasic pulse shapes.) The first pacing pulse in the series is designated SP,, while the last pulse is designated S~,+,, with n + 1, the number of pulses, running from about ten to several hundred. During application of the series of pacing pulses, tissue is activated (or, "controlled") by the pulses when each pulse is separated by an optimum cycle length. This exogenous stimulation, in a sense, creates a local "intensified ventricular tachycardia," i.e., a rapid locally propagated rhythm with a characteristic rate that only slightly exceeds the local intrinsic rate.
However, the extent of activation is not global like that observed for pacing during normal sinus rhythm (NSR). Thus, the term "controlled" is used, rather than the term "captured" as commonly used in the bradycardia pacing art, but the concept behind the two terms is the same. Instead, the spatial extent of activation, or "controlled tissue volume," is bounded by tissue rendered refractory to stimulation by propagated VF wavelets from immediately adjacent tissues. If the cycle length of the pacing pulses is optimally short, the controlled tissue volume will increase as more pacing pulses are applied. In general, the controlled tissue volume represents a volume of tissue rhythmically activating while at the same time the remaining portions of the heart are fibrillating. These volumes importantly correspond to areas in which the shock-induced field intensity is weak during attempted defibrillation.
Referring briefly to Figure 6 (which shows for illustrative purposes only the electrode configuration of Figure 1 ), as the critical tissue volume increases, the required strength of the defibrillation shock decreases. This is because during "defibroversion" the critical point (the region where critical field intensity intersects vulnerable state of refractoriness) is translocated from its initial location (CPo) to a 13 . . . (. '..' point (CP,) closer to the interelectrode axis, thus increasing the effectiveness of the defibrillation-level shocks delivered by the defibrillation electrodes (11a, 11b).
w Returning again to Figures 5 and SA, after a number of pacing pulses preceding the last such pulse, SPn r ,, the defibrillation-level shock Sp is administered between the shocking electrodes (using, for example, any of the configurations of Figures 1-4) at an optimum (SP" t , - SD) coupling interval (CI). Since the tissue in the controlled tissue volume is rhythmically activating at its optimum cycle length, stimulation during the vulnerable period can be avoided by triggering the defibrillation-level shock Sp at some optimum coupling interval.
As shown schematically in Figure 7 (which also shows for illustrative purposes only the electrode configuration of Figure 1 ), multiple defibrillation-level shocks will cardiovert successive (preferably but not necessarily successively larger) amounts of controlled tissue (CTV,_3). Adjacent regions (not shaded) are defibrillated.
Figure 8 shows the critical tissue volume (CTV) when epicar'dial defibrillation electrodes (14a, 14b) and a sutureless myocardial pacing electrode (13) are implemented, as described above in reference to Figure 3.
An alternative embodiment is shown schematically in Figure 9. Multiple hijh-strength defibrillation-level shocks (Sp~ through Sp~ ") are given after the first of a series of multiple applications of pacing-level pulses (SP, through SP~ ~
,). The first defibrillation-level shock (SD~) fails to defibrillate the entire heart.
However, the vulnerable tissue located adjacent to the controlled tissue volume border, and thus in areas where the defibrillation shock field intensity is weak, is stimulated by the propagated impulses emanating from the closely adjacent regions directly excited by the first defibrillation-level shock (SD,). Tissue in the controlled tissue volume is cardioverted and simultaneously recovers excitability over a rime period approximately equal to the mean intrinsic activation interval, as measured immediately prior to the shock, after application of the first defibrillation-level shock (Sp,). (The mean activation interval is preferably determined from the p,~E~yDED SHEEN
WO 98I13102 . PCT/US97/17233 average of from about three to ten activation intervals.). As a result, continued application of pacing-level pulses (SP, through S~,+ ~), just prior to the first intrinsic beat, controls the tissue in the original controlled tissue volume; it subsequently increases the extent of the controlled tissue volume as more tissue comes under direct influence of the rapid pacing in areas where the defibrillation-level field strength is weak (cf. Figure 7). In this way, synchronization of multiple defibrillation-level shocks is employed to cardiovert progressively larger volumes of tissue until the potentially lethal arrhythmia is terminated, a process referred to as "deceleration" of the tachyarrhythmia.
An alternative approach to deceleration of the tachyarrhythmia is also depicted in Figure 9. The original cycle length of the pacing pulses (CL,~ is relatively close to the cycle length of the local activations of the fibrillating tissues in the weak field area. After application of the first defibrillation-level shock (SDi), a new and longer cycle length (CL~+ 1) (i.e., a slower rate) is used to control the critical tissue volume. After each successive defibrillation-level pulse (Sp, to SD" +
,), the succeeding cycle length of the pacing pulses is reduced by an amount which is preferably, but not necessarily, programmable.
One explanation of the mechanism illustrated in Figure 9 considers the traditional view that in defibrillation, most or all of the heart must be subjected to a minimum shock-induced voltage gradient. However, since the heart is geometrically asymmetric, higher shock strengths are required to create the minimum gradient in regions distant from the electrodes than would be required otherwise. increasing the shock strength gradients in these remote regions accounts for the major portion of "wasted" shock strength, and also contributes to the highly non-uniform gradient distribution throughout the ventricles, which is often on the order of 30:1. In contrast, if the heart were perfectly spherical and the electrodes were diametrically opposed from each other, then shock strengths required for defibrillation would be reduced. Thus, by practicing the invention, defibrillation shock strengths required for effective defibrillation decrease, because the geometrically remote regions are effectively cardioverted, and therefore do not have to be boosted above the critical minimum for direct stimulation. However, it is important to remember that the pacing level shocks are not cardioversion shocks per se, because of their reduced voltage/energy level compared to cardioversion shocks.
S With no loss of generality in the scope of the invention, the scenarios above can be modified. For example, it is possible to intersperse one or more series of pacing pulses having different parameters such as voltage, energy, polarity, etc.
This would be done in combinations dictated by the success of either type of pacing level shock in exerting control over sufficient fibrillating myocardium to ensure 10 successful defibrillation by the defibrillation-level shock or shocks.
The inventive system is applicable to atrial arrhythmias in addition to the ventricular arrhythmias described above. In atrial applications, the time at which the defibrillation shock is applied is extremely critical, because stimulation during the ventricular vulnerable period (T-wave) could initiate ventricular fibrillation.
A second embodiment, as shown in Figure 2, is identical to the first with the exception that the defibrillation-level pulse is applied along a bi-directional pathway from the (now cathodic) RV electrode (11 a) to a common anode formed by two electrodes: one (11b) residing in the SVC (as before), the other (12) residing in the left lateral subcutis centered approximately on the mid-axillary Line. (In this, as in other embodiments, the roles of one electrode, or set of electrodes, as the anode and the other as the cathode can be interchanged without loss of generality to the invention.) Without loss of generality, the electrode (12) located in the left lateral subcutis can be an electrically active housing of the pulse generator, as discussed in more detail below.
In a third embodiment, as shown in Figure 3, the pacing-level pulses are delivered from a sutureless myocardial ("screw-in") lead (13) positioned in an apical region of the heart. Defibrillation-level pulses are applied between epicardial electrodes (14a,14b) positioned substantially opposite each other on the free walls of the ventricles.
Figure 4 shows a preferred location for a transvenous pacing electrode (15) which has been introduced into the coronary sinus, then into the great cardiac vein, and then into the ascending limb of either the anterior cardiac vein or the posterior cardiac vein, into the vasculature of the left ventricle. Because the courses of these veins are near the surface of the heart, this location gives performance very similar to that of the epicardial electrode discussed below, even though the location is within the cardiac vasculature. This embodiment places the pacing electrode (15) as close as possible to the apex of the left ventricle via a transvenous procedure, which is desirable to avoid a thoracotomy, median sternotomy, or other extensive surgical procedure.
In any of the embodiments above, an electrically active housing of the pulse generator can also serve as a defibrillation electrode, either in addition to the RV and SVC electrodes, or as a replacement to either (but typically not as a replacement for the RV electrode to ensure that sufficient ventricular mass is affected by the defibrillation shock).
The details of a scheme employing pacing-level pulses, applicable to any of the embodiments of Figures 1-4, are shown schematically in Figures 5 and SA.
The series of pacing-level pulses, denoted SP, is delivered during a period of hemodynamically unstable tachyarrhythmia, denoted schematically as VF (the tachyarrhythmia need not be only ventricular fibrillation, though that is a common condition). For this illustration, the pacing pulses have a cycle length (CL) of approximately 40 to 95 percent of the sensed cycle length of the local activations in the area of the heart in the region where the defibrillation-level shock field intensity is weak. The defibrillation shock is denoted SD.
(The defibrillation shock normally, but not necessarily, arises from a capacitor discharge and displays a biphasic truncated exponential pulse shape.
Such shocks are preferably produced by terminating the discharge waveform of a capacitor network (a single capacitor, or multiple capacitors, as dictated by morphology, available pulse generator volume, and other considerations) having capacitance in the range of 20-400 ~F; but any otherwise suitable device for producing the shocks may be employed. For example, the system of the present invention is applicable to defibrillation shocks arising from multiple-capacitor networks andlor monophasic or multiphasic pulse shapes.) The first pacing pulse in the series is designated SP,, while the last pulse is designated S~,+,, with n + 1, the number of pulses, running from about ten to several hundred. During application of the series of pacing pulses, tissue is activated (or, "controlled") by the pulses when each pulse is separated by an optimum cycle length. This exogenous stimulation, in a sense, creates a local "intensified ventricular tachycardia," i.e., a rapid locally propagated rhythm with a characteristic rate that only slightly exceeds the local intrinsic rate.
However, the extent of activation is not global like that observed for pacing during normal sinus rhythm (NSR). Thus, the term "controlled" is used, rather than the term "captured" as commonly used in the bradycardia pacing art, but the concept behind the two terms is the same. Instead, the spatial extent of activation, or "controlled tissue volume," is bounded by tissue rendered refractory to stimulation by propagated VF wavelets from immediately adjacent tissues. If the cycle length of the pacing pulses is optimally short, the controlled tissue volume will increase as more pacing pulses are applied. In general, the controlled tissue volume represents a volume of tissue rhythmically activating while at the same time the remaining portions of the heart are fibrillating. These volumes importantly correspond to areas in which the shock-induced field intensity is weak during attempted defibrillation.
Referring briefly to Figure 6 (which shows for illustrative purposes only the electrode configuration of Figure 1 ), as the critical tissue volume increases, the required strength of the defibrillation shock decreases. This is because during "defibroversion" the critical point (the region where critical field intensity intersects vulnerable state of refractoriness) is translocated from its initial location (CPo) to a 13 . . . (. '..' point (CP,) closer to the interelectrode axis, thus increasing the effectiveness of the defibrillation-level shocks delivered by the defibrillation electrodes (11a, 11b).
w Returning again to Figures 5 and SA, after a number of pacing pulses preceding the last such pulse, SPn r ,, the defibrillation-level shock Sp is administered between the shocking electrodes (using, for example, any of the configurations of Figures 1-4) at an optimum (SP" t , - SD) coupling interval (CI). Since the tissue in the controlled tissue volume is rhythmically activating at its optimum cycle length, stimulation during the vulnerable period can be avoided by triggering the defibrillation-level shock Sp at some optimum coupling interval.
As shown schematically in Figure 7 (which also shows for illustrative purposes only the electrode configuration of Figure 1 ), multiple defibrillation-level shocks will cardiovert successive (preferably but not necessarily successively larger) amounts of controlled tissue (CTV,_3). Adjacent regions (not shaded) are defibrillated.
Figure 8 shows the critical tissue volume (CTV) when epicar'dial defibrillation electrodes (14a, 14b) and a sutureless myocardial pacing electrode (13) are implemented, as described above in reference to Figure 3.
An alternative embodiment is shown schematically in Figure 9. Multiple hijh-strength defibrillation-level shocks (Sp~ through Sp~ ") are given after the first of a series of multiple applications of pacing-level pulses (SP, through SP~ ~
,). The first defibrillation-level shock (SD~) fails to defibrillate the entire heart.
However, the vulnerable tissue located adjacent to the controlled tissue volume border, and thus in areas where the defibrillation shock field intensity is weak, is stimulated by the propagated impulses emanating from the closely adjacent regions directly excited by the first defibrillation-level shock (SD,). Tissue in the controlled tissue volume is cardioverted and simultaneously recovers excitability over a rime period approximately equal to the mean intrinsic activation interval, as measured immediately prior to the shock, after application of the first defibrillation-level shock (Sp,). (The mean activation interval is preferably determined from the p,~E~yDED SHEEN
WO 98I13102 . PCT/US97/17233 average of from about three to ten activation intervals.). As a result, continued application of pacing-level pulses (SP, through S~,+ ~), just prior to the first intrinsic beat, controls the tissue in the original controlled tissue volume; it subsequently increases the extent of the controlled tissue volume as more tissue comes under direct influence of the rapid pacing in areas where the defibrillation-level field strength is weak (cf. Figure 7). In this way, synchronization of multiple defibrillation-level shocks is employed to cardiovert progressively larger volumes of tissue until the potentially lethal arrhythmia is terminated, a process referred to as "deceleration" of the tachyarrhythmia.
An alternative approach to deceleration of the tachyarrhythmia is also depicted in Figure 9. The original cycle length of the pacing pulses (CL,~ is relatively close to the cycle length of the local activations of the fibrillating tissues in the weak field area. After application of the first defibrillation-level shock (SDi), a new and longer cycle length (CL~+ 1) (i.e., a slower rate) is used to control the critical tissue volume. After each successive defibrillation-level pulse (Sp, to SD" +
,), the succeeding cycle length of the pacing pulses is reduced by an amount which is preferably, but not necessarily, programmable.
One explanation of the mechanism illustrated in Figure 9 considers the traditional view that in defibrillation, most or all of the heart must be subjected to a minimum shock-induced voltage gradient. However, since the heart is geometrically asymmetric, higher shock strengths are required to create the minimum gradient in regions distant from the electrodes than would be required otherwise. increasing the shock strength gradients in these remote regions accounts for the major portion of "wasted" shock strength, and also contributes to the highly non-uniform gradient distribution throughout the ventricles, which is often on the order of 30:1. In contrast, if the heart were perfectly spherical and the electrodes were diametrically opposed from each other, then shock strengths required for defibrillation would be reduced. Thus, by practicing the invention, defibrillation shock strengths required for effective defibrillation decrease, because the geometrically remote regions are effectively cardioverted, and therefore do not have to be boosted above the critical minimum for direct stimulation. However, it is important to remember that the pacing level shocks are not cardioversion shocks per se, because of their reduced voltage/energy level compared to cardioversion shocks.
S With no loss of generality in the scope of the invention, the scenarios above can be modified. For example, it is possible to intersperse one or more series of pacing pulses having different parameters such as voltage, energy, polarity, etc.
This would be done in combinations dictated by the success of either type of pacing level shock in exerting control over sufficient fibrillating myocardium to ensure 10 successful defibrillation by the defibrillation-level shock or shocks.
The inventive system is applicable to atrial arrhythmias in addition to the ventricular arrhythmias described above. In atrial applications, the time at which the defibrillation shock is applied is extremely critical, because stimulation during the ventricular vulnerable period (T-wave) could initiate ventricular fibrillation.
15 Consequently, implementation of the inventive system further requires measures to assure that the defibrillation shock is always applied immediately following ventricular depolarization. Since the initiation of the pacing level shock is not coupled to ventricular activity, the last pacing level shock (i.e., the shock occurring just prior to the defibrillation shock) cannot be assured to correspond to a safe (non-vulnerable) state of ventricular activity. Therefore, in a preferred embodiment, once an atrial arrhythmia is declared and after delivery of a preselected (preferably hut not necessarily programmable) number of pacing Level shock(s), a comparator looks at temporal inputs from a ventricular activation sensor (such as could be located in the apex of the right ventricle), and the time of the pacing level shock, and determines when a safe condition exists to deliver a defibrillation pulse. In this way, any pacing level shock is not delivered until the comparator fords a time when a ventricular activation falls within a pre-established optimum temporal window surrounding the pacing level shock.
Especially preferred in the atrial application, but applicable to ventricular applications, is the application of pacing-level shocks followed by at least one additional sub-defibrillation-level shock (either an additional series of pacing-level shocks, or shocks having waveforms congruent with defibrillation-level shocks but reduced in strength from defibrillation shocks), prior to the first defibrillation-level shock. For example, a first series of pacing pulses (having a first cycle length) may bring a region of tissue under control, and then be followed by a sub-defibrillation-level shock that brings additional tissue under control. At this point, a defibrillation-level shock may be appropriate; but, if not, a second series of pacing-level shocks may be applied. The second series of pacing-level shocks may, but need not necessarily, have any or a11 of the same total duration, polarity, phase, amplitude, etc. that the first series of pacing-level shocks had, as dictated by clinical considerations. However, since the region of controlled tissue is increasing, the cycle length of the second pacing-level shocks will be greater than or equal to that of the first series of pacing-level shocks. The entire process may be repeated until a defibrillation-level shock is applied to bring the heart to normal sinus rhythm.
Figure 10 illustrates schematically one of the possible system embodiments of the invention, implementing again, for illustrative purposes only, the electrode configuration of Figure l and employing the pacing-level shocks described above.
In this preferred embodiment as shown, an additional "tip" electrode (17) is added to the electrode system comprising the defibrillation electrodes (11a,11b). The additional tip electrode (17) provides a unipolar electrogram for the morphology detection component described below. The coronary sinus electrode system comprises two electrodes (18a,18b) which each provide bipolar electrograms as described below.
The pulse generator system (100) comprises subsystems, components and electronic components shown schematically within the dotted line. Inputs from the electrodes (17,18a, and 18b) go to their respective ECG amplifiers (117,118a, and l I8b), the outputs of which are used for additional processing. The unipolar , ' 17 electrogram from the tip electrode (17) provides morphology data; the bipolar electrogram from the distal (as illustrated) coronary sinus electrode (18b) provides rate data. These two inputs are processed by an arrhythmia detector (120) (any arrangement providing clinically useful arrhythmia detection is suitable). The other bipolar electrogram from the proximal (as illustrated) coronary sinus electrode (18a) is processed by a capture detector (l30) (any arrangement providing clinically successful capture detection is suitable).
The outputs of the arrhythmia and capture detectors (120, 130) are the inputs to appropriate processing circuitry as shown. The arrhythmia detector ( 120) output goes in parallel to a preferred programmable logic device (l40) which produces the pacing-level signal logic required; and additionally to the capacitor network charge/discharge controller (170) which produces the defibrillation-level signal logic required. The programmable logic device (140) also drives timing/trigger circuitry (150), as does'the output of the capture detector (130). The output of the timing/trigger circuitry (1~0) is another input to the capacitor network charge/discharge controller (170).
The pacing output circuit (160) and capacitor network charge/discharge controller (170) provide the pacing-level shocks (SP) and defibrillation-level shocks (Sp) through appropriate electrode systems to the coronary sinus electrode and defibrillation electrodes (11a, 11b).
Of course, not shown in Figure 10. but well within the skill of the art to supply, are power supplies, implantable housings and other materials for the pulse generator (100) and electrode systems, general timing, memory, and support circuitry, and the like.
The principles described above regarding use of alternate electrode configurations (such as those shown in Figures 2-4), multiple defibrillation-level shocks, etc., can all be incorporated (in whatever combination is required) by the skilled artisan into system embodiments, like that of Figure 10, without undue experimentation.
An~FnlpFp cHEE?' In confirmation of the underlying principles of the invention, experimental data indicates that rapid pacing pulses imposed during ventricular fibrillation produce local control of the myocardial tissue. Two pacing electrodes (5 mm separation) were placed flush with the epicardium of the anterobasal right ventricle of swine (N = 6, 25-30 kg) anesthetized with pentobarbital. Pledgeted sutures held a plaque such that 506 electrodes (composition: an alloy of silver and silver chloride;
diameter: 125 wm) embedded in the plaque in a 22 X 23 pattern at 1.I2 mm spacing, were flush with the epicardium. The plaque was positioned such that the pacing electrodes were approximately centered beneath it. Extracellular unipolar potentials (referenced to the left leg) were bandpass filtered between 0.5 and S00 Hz, sampled at 2 KHz (14-bit resolution, 9.766 pV step size) and recorded on videotape with a 528-channel cardiac mapping system.
The pacing pulses comprised trains of 40 (2 ms duration) rectangular monophasic stimuli applied in bipolar mode to the pacing electrodes. The trains provided a variety of coupling intervals between intrinsic ventricular fibrillation activations and the pacing pulses. To span the intrinsic activation rate during ventricular fibrillation, approximately 125 ms, a range of pacing cycle lengths of 100-140 ms was used. Stimulus strength was 10 mA, at least ten times the diastolic threshold, in an attempt to excite partially refractory tissue close to the electrodes.
Pacing stimulus thresholds were determined to the nearest 0.1 mA in each swine.
Ventricular fibrillation was induced by application of 60 Hz alternating current for 1-2 seconds between a pacing electrode sutured to the epicardium of the right ventricular apex and an indifferent electrode off the heart. Two trains of 40 shocks with the same cycle length were applied, the first train coming two seconds after induction of ventricular fibrillation, the second coming two to three seconds after the end of the first train. Nine pacing cycle lengths (100-140 ms, 5 ms steps) were tested in random order, each followed by termination of the ventricular fibrillation and repetition of the procedure until all nine were tested.
WO 98/13l02 PCT/US97/17233 Evidence of local control was determined by animating S-point dV/dt (2 frames/ms) of the extracellular potentials displayed as 22 X 23 arrays of black/gray/white points, each point in the array representing one of the 506 electrode locations. Qualitative examination of the displayed arrays showed that when pacing stimulus occurred with a long coupling interval after the previous activation of ventricular fibrillation at the pacing site, the stimulus produced activation fronts that propagated away from the pacing site. If the tissue adjacent to the pacing site then remained inactivated until the next stimulus was applied, the next stimulus also generated an activation front that was approximately 1:1 phase locked with the stimulus artifact. As the number of phase locked beats increased, the area of controlled myocardium increased. However, when the pacing cycle length was too long, intrinsic ventricular fibrillation activation fronts activated the tissue at the pacing site before the next stimulus was applied, periodicity was lost, and subsequent stimuli did not control the tissue. When pacing evoked 1:1 phase locking over major portions of the plaque, clearly observable differences in activation patterns were present when compared to either ventricular fibrillation without pacing or with pacing but absent phase locked beats.
In all six swine, local control was observed when the pacing shock fell late in the local intrinsic activation interval of the selected cardiac tissue immediately adjacent to the pacing electrodes. While this 1:1 phase locking of the extracellular electrogram to the stimulus artifact was observed in every swine, the spatial extent of control was not the same for all episodes within animals or between animals. In five of six swine, evidence of sustained control, taken to be five or more beats, occurred only when the pacing cycle length was 80-115% of the local intrinsic activation rate. (Because this is similar to coupling intervals for capture during atrial fibrillation and in functionally defined circuits of tachyarrhythmias, from this result alone it is quite reasonable to conclude that the invention is applicable to such conditions). This represented 25 of the 108 trials. On average, 4 ~ 1.5 episodes of sustained phase locking in each swine was observed, and the mean number of controlled cycles was 18 ~ 11. In nine of the 25 episodes, periodicity within the phase locked region was suddenly disrupted when tissue adjacent the pacing electrodes activated immediately prior to a stimulus. In the remaining 16 episodes, phase locking was sustained until the pacing ended, and in nine of those episodes, 5 the number of phase locked beats was 20. In one episode (120 ms pacing cycle length), a1140 stimuli produced 1:1 phase locking, with a total duration of 4.8 seconds. Within each pacing burst with sustained phase locking, the mean number of pacing stimuli applied prior to phase locking was 1 S t 10. Phase locking was significantly more frequent (p < 0.05 by x2 test) during the second pacing burst (18 10 of 25 episodes) than during the first pacing burst (seven of 25 episodes).
Two independent portions of the inventive system quantified the 1:1 phase locking. The first was a comparison of the means and variances of the interbeat intervals during three types of qualitatively identified behavior: unpaced ventricular fibrillation; pacing when the animals provided no evidence of phase locking to the 15 stimuli; and i :1 phase locking between the stimulus artifact and the local electrograms. The comparison was performed by assessing the location and dispersion of Poincare maps relating the interbeat intervals {I,~ to the previous interval {I" _ ,) for a recording electrode at the plaque border.
Representative episodes (duration approximately eight seconds) containing all three types of 20 behavior were selected for each swine. For each episode, time series from two electrodes near the plaque border were partitioned into three sub-series corresponding to each type of behavior. The mean interbeat interval I and its standard deviation were calculated for each sub-series; outlying intervals (I
< 70 ms or I > l 70 ms) were excluded. One representative Poincare section showed that during ventricular fibrillation, I varied for pacing pulses without local control and after pacing pulses ended, but was tightly clustered about the line of identity at the pacing cycle length (115 ms) during local control {0, I 15 t 1 ms).
The second independent verification employed by the inventive system was Karhunen-Loeve decomposition. The onset of pacing followed by qualitative declaration of control over the tissue was clearly associated with a marked increase in the fractional amount of total energy contained in only the first two orthogonal spatial modes; such increase is associated with higher spatial order, which indicates behavior which is repetitive and organized over its whole extent. Such results were consistent for episodes from a11 swine.
Thus, activation was synchronized over a significant portion (4-5 cm2) of the right ventricular epicardium during ventricular fibrillation by delivering pacing pulses at or near the local intrinsic activation rate.
Additional details are in KenKnight et al., Regional Capture of Fibrillating Ventricular Myocardium," Circulation Research, 77(4), 849-855 (October 199S), which is incorporated by reference.
Figure 10 illustrates schematically one of the possible system embodiments of the invention, implementing again, for illustrative purposes only, the electrode configuration of Figure l and employing the pacing-level shocks described above.
In this preferred embodiment as shown, an additional "tip" electrode (17) is added to the electrode system comprising the defibrillation electrodes (11a,11b). The additional tip electrode (17) provides a unipolar electrogram for the morphology detection component described below. The coronary sinus electrode system comprises two electrodes (18a,18b) which each provide bipolar electrograms as described below.
The pulse generator system (100) comprises subsystems, components and electronic components shown schematically within the dotted line. Inputs from the electrodes (17,18a, and 18b) go to their respective ECG amplifiers (117,118a, and l I8b), the outputs of which are used for additional processing. The unipolar , ' 17 electrogram from the tip electrode (17) provides morphology data; the bipolar electrogram from the distal (as illustrated) coronary sinus electrode (18b) provides rate data. These two inputs are processed by an arrhythmia detector (120) (any arrangement providing clinically useful arrhythmia detection is suitable). The other bipolar electrogram from the proximal (as illustrated) coronary sinus electrode (18a) is processed by a capture detector (l30) (any arrangement providing clinically successful capture detection is suitable).
The outputs of the arrhythmia and capture detectors (120, 130) are the inputs to appropriate processing circuitry as shown. The arrhythmia detector ( 120) output goes in parallel to a preferred programmable logic device (l40) which produces the pacing-level signal logic required; and additionally to the capacitor network charge/discharge controller (170) which produces the defibrillation-level signal logic required. The programmable logic device (140) also drives timing/trigger circuitry (150), as does'the output of the capture detector (130). The output of the timing/trigger circuitry (1~0) is another input to the capacitor network charge/discharge controller (170).
The pacing output circuit (160) and capacitor network charge/discharge controller (170) provide the pacing-level shocks (SP) and defibrillation-level shocks (Sp) through appropriate electrode systems to the coronary sinus electrode and defibrillation electrodes (11a, 11b).
Of course, not shown in Figure 10. but well within the skill of the art to supply, are power supplies, implantable housings and other materials for the pulse generator (100) and electrode systems, general timing, memory, and support circuitry, and the like.
The principles described above regarding use of alternate electrode configurations (such as those shown in Figures 2-4), multiple defibrillation-level shocks, etc., can all be incorporated (in whatever combination is required) by the skilled artisan into system embodiments, like that of Figure 10, without undue experimentation.
An~FnlpFp cHEE?' In confirmation of the underlying principles of the invention, experimental data indicates that rapid pacing pulses imposed during ventricular fibrillation produce local control of the myocardial tissue. Two pacing electrodes (5 mm separation) were placed flush with the epicardium of the anterobasal right ventricle of swine (N = 6, 25-30 kg) anesthetized with pentobarbital. Pledgeted sutures held a plaque such that 506 electrodes (composition: an alloy of silver and silver chloride;
diameter: 125 wm) embedded in the plaque in a 22 X 23 pattern at 1.I2 mm spacing, were flush with the epicardium. The plaque was positioned such that the pacing electrodes were approximately centered beneath it. Extracellular unipolar potentials (referenced to the left leg) were bandpass filtered between 0.5 and S00 Hz, sampled at 2 KHz (14-bit resolution, 9.766 pV step size) and recorded on videotape with a 528-channel cardiac mapping system.
The pacing pulses comprised trains of 40 (2 ms duration) rectangular monophasic stimuli applied in bipolar mode to the pacing electrodes. The trains provided a variety of coupling intervals between intrinsic ventricular fibrillation activations and the pacing pulses. To span the intrinsic activation rate during ventricular fibrillation, approximately 125 ms, a range of pacing cycle lengths of 100-140 ms was used. Stimulus strength was 10 mA, at least ten times the diastolic threshold, in an attempt to excite partially refractory tissue close to the electrodes.
Pacing stimulus thresholds were determined to the nearest 0.1 mA in each swine.
Ventricular fibrillation was induced by application of 60 Hz alternating current for 1-2 seconds between a pacing electrode sutured to the epicardium of the right ventricular apex and an indifferent electrode off the heart. Two trains of 40 shocks with the same cycle length were applied, the first train coming two seconds after induction of ventricular fibrillation, the second coming two to three seconds after the end of the first train. Nine pacing cycle lengths (100-140 ms, 5 ms steps) were tested in random order, each followed by termination of the ventricular fibrillation and repetition of the procedure until all nine were tested.
WO 98/13l02 PCT/US97/17233 Evidence of local control was determined by animating S-point dV/dt (2 frames/ms) of the extracellular potentials displayed as 22 X 23 arrays of black/gray/white points, each point in the array representing one of the 506 electrode locations. Qualitative examination of the displayed arrays showed that when pacing stimulus occurred with a long coupling interval after the previous activation of ventricular fibrillation at the pacing site, the stimulus produced activation fronts that propagated away from the pacing site. If the tissue adjacent to the pacing site then remained inactivated until the next stimulus was applied, the next stimulus also generated an activation front that was approximately 1:1 phase locked with the stimulus artifact. As the number of phase locked beats increased, the area of controlled myocardium increased. However, when the pacing cycle length was too long, intrinsic ventricular fibrillation activation fronts activated the tissue at the pacing site before the next stimulus was applied, periodicity was lost, and subsequent stimuli did not control the tissue. When pacing evoked 1:1 phase locking over major portions of the plaque, clearly observable differences in activation patterns were present when compared to either ventricular fibrillation without pacing or with pacing but absent phase locked beats.
In all six swine, local control was observed when the pacing shock fell late in the local intrinsic activation interval of the selected cardiac tissue immediately adjacent to the pacing electrodes. While this 1:1 phase locking of the extracellular electrogram to the stimulus artifact was observed in every swine, the spatial extent of control was not the same for all episodes within animals or between animals. In five of six swine, evidence of sustained control, taken to be five or more beats, occurred only when the pacing cycle length was 80-115% of the local intrinsic activation rate. (Because this is similar to coupling intervals for capture during atrial fibrillation and in functionally defined circuits of tachyarrhythmias, from this result alone it is quite reasonable to conclude that the invention is applicable to such conditions). This represented 25 of the 108 trials. On average, 4 ~ 1.5 episodes of sustained phase locking in each swine was observed, and the mean number of controlled cycles was 18 ~ 11. In nine of the 25 episodes, periodicity within the phase locked region was suddenly disrupted when tissue adjacent the pacing electrodes activated immediately prior to a stimulus. In the remaining 16 episodes, phase locking was sustained until the pacing ended, and in nine of those episodes, 5 the number of phase locked beats was 20. In one episode (120 ms pacing cycle length), a1140 stimuli produced 1:1 phase locking, with a total duration of 4.8 seconds. Within each pacing burst with sustained phase locking, the mean number of pacing stimuli applied prior to phase locking was 1 S t 10. Phase locking was significantly more frequent (p < 0.05 by x2 test) during the second pacing burst (18 10 of 25 episodes) than during the first pacing burst (seven of 25 episodes).
Two independent portions of the inventive system quantified the 1:1 phase locking. The first was a comparison of the means and variances of the interbeat intervals during three types of qualitatively identified behavior: unpaced ventricular fibrillation; pacing when the animals provided no evidence of phase locking to the 15 stimuli; and i :1 phase locking between the stimulus artifact and the local electrograms. The comparison was performed by assessing the location and dispersion of Poincare maps relating the interbeat intervals {I,~ to the previous interval {I" _ ,) for a recording electrode at the plaque border.
Representative episodes (duration approximately eight seconds) containing all three types of 20 behavior were selected for each swine. For each episode, time series from two electrodes near the plaque border were partitioned into three sub-series corresponding to each type of behavior. The mean interbeat interval I and its standard deviation were calculated for each sub-series; outlying intervals (I
< 70 ms or I > l 70 ms) were excluded. One representative Poincare section showed that during ventricular fibrillation, I varied for pacing pulses without local control and after pacing pulses ended, but was tightly clustered about the line of identity at the pacing cycle length (115 ms) during local control {0, I 15 t 1 ms).
The second independent verification employed by the inventive system was Karhunen-Loeve decomposition. The onset of pacing followed by qualitative declaration of control over the tissue was clearly associated with a marked increase in the fractional amount of total energy contained in only the first two orthogonal spatial modes; such increase is associated with higher spatial order, which indicates behavior which is repetitive and organized over its whole extent. Such results were consistent for episodes from a11 swine.
Thus, activation was synchronized over a significant portion (4-5 cm2) of the right ventricular epicardium during ventricular fibrillation by delivering pacing pulses at or near the local intrinsic activation rate.
Additional details are in KenKnight et al., Regional Capture of Fibrillating Ventricular Myocardium," Circulation Research, 77(4), 849-855 (October 199S), which is incorporated by reference.
Claims (17)
1.~A system for sypplying therapeutic electrical energy; comprising:
a first generator of a plurality of pacing pulses;
a second generator of at least one defibrillation-level shock;
a first electrode system coupled to the first generator for delivering the pacing pulses to a first location including at least a region of selected cardiac tissue having a relatively low susceptibility to defibrillation-level shock field strength; and a second electrode system coupled to the second generator for delivering the defibrillation-level shock to the heart from a second location, in which the system further comprises timers which coordinate delivery of a first defibrillation-level shock to occur with of after the delivery of a last pacing pulse.
a first generator of a plurality of pacing pulses;
a second generator of at least one defibrillation-level shock;
a first electrode system coupled to the first generator for delivering the pacing pulses to a first location including at least a region of selected cardiac tissue having a relatively low susceptibility to defibrillation-level shock field strength; and a second electrode system coupled to the second generator for delivering the defibrillation-level shock to the heart from a second location, in which the system further comprises timers which coordinate delivery of a first defibrillation-level shock to occur with of after the delivery of a last pacing pulse.
2. The system of claim 1, wherein the timers coordinate the delivery of a first pacing pulse by the first electrode system prior to when the second electrode system delivers the first defibrillation shock.
3. The system of claim 1, wherein the timers coordinate the delivery of the last pacind pulse by the first electrode system simultaneously with the application of the first defibrillation shock by the second electrode system.
4. The system of claim 1, wherein the first electrode system applies at last pacing pulse within about one means activation interval, calculated by the timers immediately prior to a first pacing pulse, from the first defibrillation shock delivered by the second electrode system.
5. The system of claim 1, wherein the selected cardiac tissue is ventricular tissue.
6. The system of claim 1, wherein the selected cardiac tissues are regions of fibrillating myocardium characterized by approximately a 1:1 phase lock of a local electrogram of that region to a stimulus artifact in that region as sensed by the system.
7. The system of claim 1, wherein the selected cardiac tissue is atrial tissue, and the timers further postpones application of any defibrillation-level.
shock which would occur within the T-wave of ventricular activation cycle until after ventricular depolarization.
shock which would occur within the T-wave of ventricular activation cycle until after ventricular depolarization.
8. The system of claim 1, wherein the second generator generates at least one sub-defibrillation-level shock having morphology congruent with a defibrillation-level shock but strength below a defibrillation threshold of the selected cardiac tissue, by terminating the discharge waveform of the capacitor network.
9. The system of claim 8, wherein the second generator has a capacitor network having a capacitance in the range of approximately 20 to 400 µF.
10. The system of claim 1, wherein the first and second generators are combined into a single implantable device.
11. The system of claim 8, wherein the at least one sub-defibrillation-level shock is a pacing-level shock.
12. The system of claim 1, wherein the first electrode system delivers a plurality of the at least one pacing level shock in a periodic manner to reduce shock strength requirements of a defibrillation-level shock subsequently applied from the second electrode system.
13. The system of claim 12, wherein the timers coordinate the delivery of the plurality of the at least one pacing level shock to the defibrillation level shock subsequently applied from the second electrode system.
14. The system of claim 1, wherein the first electrode system delivers a plurality of the at least one pacing level shocks and the system determines that control has been exerted over successive regions of fibrillating myocardium.
15. The system of claim 1, wherein the first electrode system includes at least a first pacing electrode and a second pacing electrode, where the first pacing electrode delivers the at least one pacing level shock to the first location and the second pacing electrode delivers at least a second pacing level shock to a second location including at least a second region of selected cardiac tissue having a relatively low susceptibility to defibrillation-level shock field strength.
16. The system of claim 15, wherein the first generator generates a first pacing shock profile to be delivered by the first pacing electrode, and generates a second pacing shock profile that is similar or identical to the first pacing shock profile to be delivered by the second pacing electrode.
17. The system of claim 15, wherein the first generator generates a first pacing shock profile to be delivered by the first pacing electrode, and generates a second pacing shock profile that is different than the first pacing shock profile to be delivered by the second pacing electrode.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/720,360 | 1996-09-27 | ||
| US08/720,360 US5797967A (en) | 1996-09-27 | 1996-09-27 | System and method to reduce defibrillation requirements |
| PCT/US1997/017233 WO1998013102A1 (en) | 1996-09-27 | 1997-09-25 | System to reduce defibrillation requirements |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2267162A1 true CA2267162A1 (en) | 1998-04-02 |
Family
ID=24893726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002267162A Abandoned CA2267162A1 (en) | 1996-09-27 | 1997-09-25 | System to reduce defibrillation requirements |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US5797967A (en) |
| EP (1) | EP1007151A1 (en) |
| CA (1) | CA2267162A1 (en) |
| WO (1) | WO1998013102A1 (en) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9289618B1 (en) | 1996-01-08 | 2016-03-22 | Impulse Dynamics Nv | Electrical muscle controller |
| US8321013B2 (en) | 1996-01-08 | 2012-11-27 | Impulse Dynamics, N.V. | Electrical muscle controller and pacing with hemodynamic enhancement |
| IL125136A (en) * | 1996-01-08 | 2003-07-31 | Impulse Dynamics Nv | Electrical cardiac muscle controller method and apparatus |
| US8825152B2 (en) | 1996-01-08 | 2014-09-02 | Impulse Dynamics, N.V. | Modulation of intracellular calcium concentration using non-excitatory electrical signals applied to the tissue |
| US7167748B2 (en) | 1996-01-08 | 2007-01-23 | Impulse Dynamics Nv | Electrical muscle controller |
| US9713723B2 (en) | 1996-01-11 | 2017-07-25 | Impulse Dynamics Nv | Signal delivery through the right ventricular septum |
| US6415178B1 (en) * | 1996-09-16 | 2002-07-02 | Impulse Dynamics N.V. | Fencing of cardiac muscles |
| US7908003B1 (en) | 1996-08-19 | 2011-03-15 | Mr3 Medical Llc | System and method for treating ischemia by improving cardiac efficiency |
| US6292050B1 (en) | 1997-01-29 | 2001-09-18 | Cardiac Pacemakers, Inc. | Current and temperature compensated voltage reference having improved power supply rejection |
| US6112117A (en) * | 1997-05-06 | 2000-08-29 | Cardiac Pacemakers, Inc. | Method and apparatus for treating cardiac arrhythmia using electrogram features |
| US6152954A (en) | 1998-07-22 | 2000-11-28 | Cardiac Pacemakers, Inc. | Single pass lead having retractable, actively attached electrode for pacing and sensing |
| US6556862B2 (en) * | 1998-03-19 | 2003-04-29 | Cardiac Pacemakers, Inc. | Method and apparatus for treating supraventricular tachyarrhythmias |
| US6246906B1 (en) | 1998-03-19 | 2001-06-12 | Cardiac Pacemakers, Inc. | System and method for treating atrial arrhythmias |
| US6091989A (en) * | 1998-04-08 | 2000-07-18 | Swerdlow; Charles D. | Method and apparatus for reduction of pain from electric shock therapies |
| US6094596A (en) * | 1998-06-19 | 2000-07-25 | Angeron Corporation | Transvenous defibrillation lead system for use in middle cardiac vein |
| US6154672A (en) | 1998-06-22 | 2000-11-28 | Pacesetter, Inc. | Method and apparatus for improving the probability of success of defibrillation shocks |
| US6463334B1 (en) | 1998-11-02 | 2002-10-08 | Cardiac Pacemakers, Inc. | Extendable and retractable lead |
| US6501990B1 (en) | 1999-12-23 | 2002-12-31 | Cardiac Pacemakers, Inc. | Extendable and retractable lead having a snap-fit terminal connector |
| US6292691B1 (en) * | 1998-08-07 | 2001-09-18 | Pacesetter, Inc. | Atrial defibrillation methods and apparatus |
| US6081746A (en) * | 1998-08-07 | 2000-06-27 | Pacesetter, Inc. | Atrial defibrillation methods and apparatus |
| US6085116A (en) * | 1998-08-07 | 2000-07-04 | Pacesetter, Inc. | Atrial defibrillation methods and apparatus |
| EP2208782B1 (en) | 1999-02-04 | 2017-05-31 | Pluristem Ltd. | Method and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells |
| US9101765B2 (en) | 1999-03-05 | 2015-08-11 | Metacure Limited | Non-immediate effects of therapy |
| US8666495B2 (en) | 1999-03-05 | 2014-03-04 | Metacure Limited | Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar |
| US8019421B2 (en) | 1999-03-05 | 2011-09-13 | Metacure Limited | Blood glucose level control |
| US8346363B2 (en) | 1999-03-05 | 2013-01-01 | Metacure Limited | Blood glucose level control |
| US8700161B2 (en) | 1999-03-05 | 2014-04-15 | Metacure Limited | Blood glucose level control |
| US6647291B1 (en) | 1999-04-05 | 2003-11-11 | Medtronic, Inc. | Method and apparatus for cardiac defibrillation |
| AU4776000A (en) | 1999-05-26 | 2000-12-18 | Impulse Dynamic Nv | Shockless defibrillation |
| US6363288B1 (en) | 1999-08-20 | 2002-03-26 | Pacesetter, Inc. | CS lead with single site sensing and dual site pacing |
| US6993385B1 (en) | 1999-10-25 | 2006-01-31 | Impulse Dynamics N.V. | Cardiac contractility modulation device having anti-arrhythmic capabilities and a method of operating thereof |
| AU1049901A (en) | 1999-10-25 | 2001-05-08 | Impulse Dynamics N.V. | Cardiac contractility modulation device having anti-arrhythmic capabilities and a method of operating thereof |
| US6363281B1 (en) | 2000-05-16 | 2002-03-26 | Cardiac Pacemakers, Inc. | Cardiac rhythm management system and method |
| US6574512B1 (en) | 2000-08-28 | 2003-06-03 | Cardiac Pacemakers, Inc. | Lead system with main lead and transverse lead |
| US7130682B2 (en) * | 2000-12-26 | 2006-10-31 | Cardiac Pacemakers, Inc. | Pacing and sensing vectors |
| US6668193B2 (en) * | 2001-01-04 | 2003-12-23 | Cardiac Pacemakers, Inc. | Method and apparatus for cardiac shock therapy |
| US6754531B1 (en) * | 2001-10-19 | 2004-06-22 | Pacesetter, Inc. | Anti-tachycardia pacing methods and devices |
| US7139610B2 (en) * | 2002-04-26 | 2006-11-21 | Medtronic, Inc. | Capture management in multi-site pacing |
| US7110815B2 (en) * | 2002-05-06 | 2006-09-19 | Cardiac Pacemakers, Inc. | System and method for providing temporary stimulation therapy to optimize chronic electrical performance for electrodes used in conjunction with a cardiac rhythm management system |
| US7203543B2 (en) * | 2002-10-23 | 2007-04-10 | Cardiac Pacemakers, Inc. | Method and system for detecting capture using a coronary vein electrode |
| WO2004070396A2 (en) | 2003-02-10 | 2004-08-19 | N-Trig Ltd. | Touch detection for a digitizer |
| US7392081B2 (en) * | 2003-02-28 | 2008-06-24 | Cardiac Pacemakers, Inc. | Subcutaneous cardiac stimulator employing post-shock transthoracic asystole prevention pacing |
| US7702388B2 (en) | 2003-02-28 | 2010-04-20 | Cardiac Pacemakers, Inc. | Cardiac therapy triggered by capture verification |
| US7840262B2 (en) | 2003-03-10 | 2010-11-23 | Impulse Dynamics Nv | Apparatus and method for delivering electrical signals to modify gene expression in cardiac tissue |
| US11439815B2 (en) | 2003-03-10 | 2022-09-13 | Impulse Dynamics Nv | Protein activity modification |
| US7570997B2 (en) * | 2003-04-11 | 2009-08-04 | Cardiac Pacemakers, Inc. | Subcutaneous cardiac rhythm management with asystole prevention therapy |
| US7302294B2 (en) | 2003-04-11 | 2007-11-27 | Cardiac Pacemakers, Inc. | Subcutaneous cardiac sensing and stimulation system employing blood sensor |
| US7979122B2 (en) | 2003-04-11 | 2011-07-12 | Cardiac Pacemakers, Inc. | Implantable sudden cardiac death prevention device with reduced programmable feature set |
| US8792985B2 (en) | 2003-07-21 | 2014-07-29 | Metacure Limited | Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar |
| US8002553B2 (en) | 2003-08-18 | 2011-08-23 | Cardiac Pacemakers, Inc. | Sleep quality data collection and evaluation |
| US7887493B2 (en) | 2003-09-18 | 2011-02-15 | Cardiac Pacemakers, Inc. | Implantable device employing movement sensing for detecting sleep-related disorders |
| EP1670547B1 (en) | 2003-08-18 | 2008-11-12 | Cardiac Pacemakers, Inc. | Patient monitoring system |
| US8352031B2 (en) | 2004-03-10 | 2013-01-08 | Impulse Dynamics Nv | Protein activity modification |
| US11779768B2 (en) | 2004-03-10 | 2023-10-10 | Impulse Dynamics Nv | Protein activity modification |
| US7379771B2 (en) * | 2004-11-01 | 2008-05-27 | Cardiac Pacemakers, Inc. | Conduction based automatic therapy selection |
| US8175702B2 (en) | 2004-11-04 | 2012-05-08 | The Washington University | Method for low-voltage termination of cardiac arrhythmias by effectively unpinning anatomical reentries |
| EP1827571B1 (en) | 2004-12-09 | 2016-09-07 | Impulse Dynamics NV | Protein activity modification |
| US8874204B2 (en) * | 2004-12-20 | 2014-10-28 | Cardiac Pacemakers, Inc. | Implantable medical devices comprising isolated extracellular matrix |
| US7981065B2 (en) | 2004-12-20 | 2011-07-19 | Cardiac Pacemakers, Inc. | Lead electrode incorporating extracellular matrix |
| US9821158B2 (en) | 2005-02-17 | 2017-11-21 | Metacure Limited | Non-immediate effects of therapy |
| WO2006097934A2 (en) | 2005-03-18 | 2006-09-21 | Metacure Limited | Pancreas lead |
| EP1898991B1 (en) | 2005-05-04 | 2016-06-29 | Impulse Dynamics NV | Protein activity modification |
| US7593771B2 (en) * | 2005-06-21 | 2009-09-22 | Cardiac Pacemakers, Inc. | Post-shock management of implantable cardiac device features |
| US20070282376A1 (en) | 2006-06-06 | 2007-12-06 | Shuros Allan C | Method and apparatus for neural stimulation via the lymphatic system |
| US8983598B2 (en) * | 2006-10-04 | 2015-03-17 | Cardiac Pacemakers, Inc. | System for neurally-mediated anti-arrhythmic therapy |
| CA2673971C (en) * | 2006-11-13 | 2016-07-19 | Washington University Of St. Louis | Cardiac pacing using the inferior nodal extension |
| US8560066B2 (en) | 2007-12-11 | 2013-10-15 | Washington University | Method and device for three-stage atrial cardioversion therapy |
| US8874208B2 (en) | 2007-12-11 | 2014-10-28 | The Washington University | Methods and devices for three-stage ventricular therapy |
| ES2574985T3 (en) * | 2007-12-11 | 2016-06-23 | Washington University In St. Louis | Termination device for atrial tachyarrhythmias with low energy |
| US8934975B2 (en) | 2010-02-01 | 2015-01-13 | Metacure Limited | Gastrointestinal electrical therapy |
| RU2013108065A (en) * | 2010-07-23 | 2014-08-27 | Рафаэл Девелопмент Корпорэйшн Лтд. | IMPROVED USE OF ELECTRIC FIELDS TO REDUCE THE PATIENT'S INCONVENIENCE DURING DEFIBRILLATION |
| US8473051B1 (en) | 2010-12-29 | 2013-06-25 | Cardialen, Inc. | Low-energy atrial cardioversion therapy with controllable pulse-shaped waveforms |
| US9079034B2 (en) | 2012-05-02 | 2015-07-14 | Technology Innovation, Llc | Method for stabilization of cardiac tissue contractions using limit cycles |
| EP2854940B1 (en) | 2012-05-31 | 2022-07-06 | Zoll Medical Corporation | Medical monitoring and treatment device with external pacing |
| US10328266B2 (en) | 2012-05-31 | 2019-06-25 | Zoll Medical Corporation | External pacing device with discomfort management |
| US11097107B2 (en) | 2012-05-31 | 2021-08-24 | Zoll Medical Corporation | External pacing device with discomfort management |
| US10905884B2 (en) | 2012-07-20 | 2021-02-02 | Cardialen, Inc. | Multi-stage atrial cardioversion therapy leads |
| US8868178B2 (en) | 2012-12-11 | 2014-10-21 | Galvani, Ltd. | Arrhythmia electrotherapy device and method with provisions for mitigating patient discomfort |
| WO2017121702A1 (en) | 2016-01-11 | 2017-07-20 | Sorin Crm Sas | Active implantable medical defibrillation device, including improved means for discriminating between external noise and probe breakage and for characterising tachyarrhythmias |
| EP3342455B1 (en) * | 2017-01-03 | 2019-06-26 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Apparatus for terminating or unpinning rotating electric activity in a cardiac tissue |
| US10946207B2 (en) | 2017-05-27 | 2021-03-16 | West Affum Holdings Corp. | Defibrillation waveforms for a wearable cardiac defibrillator |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4693253A (en) * | 1981-03-23 | 1987-09-15 | Medtronic, Inc. | Automatic implantable defibrillator and pacer |
| US4708145A (en) * | 1982-06-01 | 1987-11-24 | Medtronic, Inc. | Sequential-pulse, multiple pathway defibrillation method |
| US4548203A (en) * | 1982-06-01 | 1985-10-22 | Purdue Research Foundation | Sequential-pulse, multiple pathway defibrillation method |
| US4559946A (en) * | 1982-06-18 | 1985-12-24 | Mieczyslaw Mirowski | Method and apparatus for correcting abnormal cardiac activity by low energy shocks |
| JPH0760169B2 (en) * | 1984-11-02 | 1995-06-28 | 三洋電機株式会社 | Logic circuit simulation method and simulator |
| US4637397A (en) * | 1985-05-30 | 1987-01-20 | Case Western Reserve University | Triphasic wave defibrillation |
| US4774952A (en) * | 1985-06-20 | 1988-10-04 | Medtronic, Inc. | Cardioversion and defibrillation lead |
| US4641656A (en) * | 1985-06-20 | 1987-02-10 | Medtronic, Inc. | Cardioversion and defibrillation lead method |
| DE3535504A1 (en) * | 1985-10-04 | 1987-04-09 | Siemens Ag | HEART PACEMAKER |
| US4800883A (en) * | 1986-04-02 | 1989-01-31 | Intermedics, Inc. | Apparatus for generating multiphasic defibrillation pulse waveform |
| US4834100A (en) * | 1986-05-12 | 1989-05-30 | Charms Bernard L | Apparatus and method of defibrillation |
| US4788980A (en) * | 1986-07-18 | 1988-12-06 | Siemens-Pacesetter, Inc. | Pacemaker having PVC response and PMT terminating features |
| US4827932A (en) * | 1987-02-27 | 1989-05-09 | Intermedics Inc. | Implantable defibrillation electrodes |
| US4821723A (en) * | 1987-02-27 | 1989-04-18 | Intermedics Inc. | Biphasic waveforms for defibrillation |
| US4944300A (en) * | 1987-04-28 | 1990-07-31 | Sanjeev Saksena | Method for high energy defibrillation of ventricular fibrillation in humans without a thoracotomy |
| US4787389A (en) * | 1987-07-16 | 1988-11-29 | Tnc Medical Devices Pte. Ltd. | Using an implantable antitachycardia defibrillator circuit |
| US4984572A (en) * | 1988-08-18 | 1991-01-15 | Leonard Bloom | Hemodynamically responsive system for and method of treating a malfunctioning heart |
| US5007422A (en) * | 1989-06-06 | 1991-04-16 | Ventritex, Inc. | Method for combiner cardiac pacing and defibrillation |
| US4996984A (en) * | 1989-09-26 | 1991-03-05 | Eli Lilly And Company | Defibrillation method |
| US5161528A (en) * | 1989-09-26 | 1992-11-10 | Eli Lilly And Company | Defibrillation method and apparatus |
| US5111812A (en) * | 1990-01-23 | 1992-05-12 | Cardiac Pacemakers, Inc. | Defilbrillation electrode having smooth current distribution |
| US5154485A (en) * | 1990-05-11 | 1992-10-13 | Fleishman Gregg R | Spring plate furniture |
| US5085213A (en) * | 1990-06-01 | 1992-02-04 | Leonard Bloom | Hemodynamically responsive system for and method of treating a malfunctioning heart |
| US5074301A (en) * | 1990-07-16 | 1991-12-24 | Telectronics Pacing Systems, Inc. | Apparatus and method for atrial pace before ventricular shock in dual chamber arrhythmia control system |
| US5163428A (en) * | 1990-10-11 | 1992-11-17 | Ventritex, Inc. | Implantable cardiac defibrillator with current leakage detecting means |
| US5178140A (en) * | 1991-09-05 | 1993-01-12 | Telectronics Pacing Systems, Inc. | Implantable medical devices employing capacitive control of high voltage switches |
| US5314448A (en) * | 1991-10-28 | 1994-05-24 | Angeion Corporation | Process for defibrillation pretreatment of a heart |
| US5275621A (en) * | 1992-04-13 | 1994-01-04 | Medtronic, Inc. | Method and apparatus for terminating tachycardia |
| SE9202663D0 (en) * | 1992-09-16 | 1992-09-16 | Siemens Elema Ab | IMPLANTABLE HEART DEFIBRILLATOR |
| SE9202665D0 (en) * | 1992-09-16 | 1992-09-16 | Siemens Elema Ab | HJAERTDEFIBRILLATOR |
| SE9202662D0 (en) * | 1992-09-16 | 1992-09-16 | Siemens Elema Ab | DEVICE FOR CREATING STIMULATION PULSES AND DEFIBRILLATION SHOCKS CREATED HEART DEFIBRILLATION SEQUENCES |
| US5265600A (en) * | 1992-10-23 | 1993-11-30 | Incontrol, Inc. | Atrial defibrillator and method for providing post-cardioversion pacing |
| US5282836A (en) * | 1992-10-23 | 1994-02-01 | Incontrol, Inc. | Atrial defibrillator and method for providing pre-cardioversion pacing |
| US5522853A (en) * | 1992-10-27 | 1996-06-04 | Angeion Corporation | Method and apparatus for progressive recruitment of cardiac fibrillation |
| US5350401A (en) * | 1993-03-26 | 1994-09-27 | Siemens Pacesetter, Inc. | Implantable cardioverter/defibrillator device having means for determining and treating low amplitude ventricular fibrillation and method thereof |
| US5489293A (en) * | 1993-08-31 | 1996-02-06 | Ventritex, Inc. | Method and apparatus for treating cardiac tachyarrhythmia |
| US5562708A (en) * | 1994-04-21 | 1996-10-08 | Medtronic, Inc. | Method and apparatus for treatment of atrial fibrillation |
| EP0756507B1 (en) * | 1994-04-21 | 1999-05-12 | Medtronic, Inc. | Treatment of atrial fibrillation |
| US5713924A (en) * | 1995-06-27 | 1998-02-03 | Medtronic, Inc. | Defibrillation threshold reduction system |
-
1996
- 1996-09-27 US US08/720,360 patent/US5797967A/en not_active Expired - Lifetime
-
1997
- 1997-09-25 WO PCT/US1997/017233 patent/WO1998013102A1/en not_active Application Discontinuation
- 1997-09-25 CA CA002267162A patent/CA2267162A1/en not_active Abandoned
- 1997-09-25 EP EP97944456A patent/EP1007151A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US5797967A (en) | 1998-08-25 |
| EP1007151A1 (en) | 2000-06-14 |
| WO1998013102A1 (en) | 1998-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5797967A (en) | System and method to reduce defibrillation requirements | |
| WO1998013102A9 (en) | System to reduce defibrillation requirements | |
| US10842998B2 (en) | Antitachycardia pacing pulse from a subcutaneous defibrillator | |
| US4384585A (en) | Synchronous intracardiac cardioverter | |
| EP0756507B1 (en) | Treatment of atrial fibrillation | |
| EP0837714B1 (en) | Defibrillation threshold reduction pacing system | |
| US6275730B1 (en) | Method and apparatus for treating cardiac arrythmia | |
| US6266563B1 (en) | Method and apparatus for treating cardiac arrhythmia | |
| US5978705A (en) | Method and apparatus for treating cardiac arrhythmia using auxiliary pulse | |
| US5853426A (en) | Method and apparatus for delivering atrial defibrillaton therapy with improved effectiveness | |
| US6085116A (en) | Atrial defibrillation methods and apparatus | |
| US5562708A (en) | Method and apparatus for treatment of atrial fibrillation | |
| US5181511A (en) | Apparatus and method for antitachycardia pacing using a virtual electrode | |
| US5928270A (en) | Method and apparatus for incremental cardioversion or defibrillation | |
| US6081746A (en) | Atrial defibrillation methods and apparatus | |
| US6154672A (en) | Method and apparatus for improving the probability of success of defibrillation shocks | |
| US5391185A (en) | Atrial cardioverter with ventricular protection | |
| CA2192847C (en) | Defibrillator shock timing in fibrillatory cycle interval | |
| CA2397852A1 (en) | Dual-chambered pacemaker and defibrillator | |
| US6292691B1 (en) | Atrial defibrillation methods and apparatus | |
| Strickberger et al. | Effect of first-phase polarity of biphasic shocks on defibrillation threshold with a single transvenous lead system | |
| US20030163166A1 (en) | Implantable defibrillator design with optimized multipulse waveform delivery and method for using | |
| US20040127946A1 (en) | Method and apparatus for atrial tachyarrhythmia cardioversion | |
| EP0759312A2 (en) | Cardiac assist device | |
| EP1216075A1 (en) | Method and apparatus for treating cardiac arrhythmia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |